Tetraphase Pharmaceuticals, Inc.

480 Arsenal Street, Suite 110

Watertown, MA  02472

Tel: 617.715.3600


Leadership:
Guy Macdonald, BSc
President & CEO


Website:
www.tphase.com


Information:
info@tphase.com

Tetraphase Pharmaceuticals, Inc.

Flagship Partners:  Doug Cole
Initial Investment: 
2006
Status: 
Public

Tetraphase Pharmaceuticals (NASDAQ: TTPH) is a publicly traded clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, including many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase's lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy. Tetraphase has created more than 3,000 novel tetracycline analogs using its technology platform; in addition to eravacycline, Tetraphase has generated multiple preclinical antibiotic candidates that are currently being evaluated for clinical suitability.

Doug Cole is on the Board of Directors.